36 results
6-K/A
EX-99.2
QNTM
Quantum BioPharma Ltd
19 Aug 24
Condensed consolidated interim financial statements
5:18pm
of approval from the Alfred Ethics Committee in Australia to proceed with a Phase 1 clinical trial of Lucid-201, as a novel drug candidate … TRIAL). This clinical trial application is submitted for review by a human ethics review committee ("HREC") in Australia, a first step to obtain
6-K
EX-99.2
QNTM
Quantum BioPharma Ltd
14 Aug 24
Condensed consolidated interim financial statements
6:13am
of approval from the Alfred Ethics Committee in Australia to proceed with a Phase 1 clinical trial of Lucid-201, as a novel drug candidate … TRIAL). This clinical trial application is submitted for review by a human ethics review committee ("HREC") in Australia, a first step to obtain
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
8 Jul 24
Annual General and Special Meeting of the Shareholders to Be Held on Management Information Circular
5:16pm
to promote good governance and ethics in the decision- making process of the Board.
The attendance record of each of the directors for Board meetings … and Ethics (the “Code”) which provides guidelines surrounding, among other items, compliance with applicable laws, conflicts of interest, certain
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
27 Jun 24
Current report (foreign)
7:34am
EXHIBIT 99.1
FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS … approval by the human ethics review committee (HREC) in Australia for its trial entitled “A Phase 1, Randomized, Double-Blind, Placebo-Controlled
6-K
EX-99.2
QNTM
Quantum BioPharma Ltd
15 May 24
Condensed consolidated interim financial statements
6:02am
for multiple sclerosis.
On March 22, 2023, FSD Australia received the certificate of approval from the Alfred Ethics Committee in Australia to proceed … by a human ethics review committee ("HREC") in Australia, a first step to obtain permission to initiate the clinical trial. Recruitment of healthy volunteers
6-K
EX-99.1
0czous0vs7c
7 May 24
Current report (foreign)
8:31am
6-K
EX-99.1
a2k0 6a7js
11 Mar 24
Current report (foreign)
8:00am
424B5
utxsgd1
16 Feb 24
Prospectus supplement for primary offering
6:36pm
F-3
v4gk6agz90i7ur kilr
22 Dec 23
Shelf registration (foreign)
6:49pm
6-K
EX-99.2
lv64 7db2e3
15 Nov 23
Condensed consolidated interim financial statements
12:00am
6-K
EX-99.2
0cpw2izh3 2cxy
20 Jul 23
Condensed consolidated interim financial statements
5:05pm
6-K
EX-99.2
8p2ibhi0w0 r2
12 May 23
Condensed consolidated interim financial statements
6:55pm
6-K
EX-99.1
ai5p sdrkbo7i7mnbq
23 May 22
Annual General Meeting of the Shareholders
4:29pm
20-F
3vgjy4 fyg
31 Mar 22
Annual report (foreign)
8:09am
6-K
EX-99.1
5s4pjl7 q66ftmur0
5 May 21
Current report (foreign)
11:30am
6-K
EX-99.1
uls 1x6oeqf
23 Apr 21
Current report (foreign)
5:24pm
40-F
qttec 0vtydn
17 Mar 21
Annual report (Canada)
12:00am